Stock Events

Hepion Pharmaceuticals 

$2.42
27
+$0.03+1.26% Friday 21:30

Statistics

Day High
2.59
Day Low
2.3
52W High
20.66
52W Low
1.49
Volume
99,946
Avg. Volume
137,137
Mkt Cap
10.5M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-3.08
-2.05
-1.03
0
Expected EPS
-3.08
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HEPA. It's not an investment recommendation.

Analyst Ratings

0$Average Price Target
The highest estimate is $0.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Show more...
CEO
Robert Foster
Employees
20
Country
US
ISIN
US4268971045
WKN
000A2PN6W

Listings